Investor Alert

Jan. 26, 2021, 2:24 a.m. EST

AstraZeneca's asthma treatment gets China approval

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

By Anthony O. Goriainoff

AstraZeneca PLC said Tuesday that Symbicort was approved in China as a treatment for mild asthma in patients over the age of 12.

The U.K. pharmaceutical giant said the approval by the National Medical Products Administration was based on the positive results of the SYGMA 1 and SYGMA 2 Phase 3 trials. Those evaluated the efficacy of Symbicort Turbuhaler taken, as needed, as an anti-inflammatory reliever compared with the standard of care therapies in mild asthma, the company said.

The company said Symbicort was already approved in China for patients with moderate to severe asthma.

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.